Chloroaluminum phthalocyanine tetrasulfonate delivered via acid-labile diplasmenylcholine-folate liposomes: Intracellular localization and synergistic phototoxicity

Qualls, Marquita M.; Thompson, David H.

doi:10.1002/ijc.1339

Cited by 70 publications

(39 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FAliposomes containing the DPPlsC lipid and loaded with Ara-C displayed a 6000-fold increase in cytotoxicity to KB cells when compared to free Ara-C. A similar formulation was also used for the delivery of chloroaluminium phthalocyanine tetrasulfonate (AlPcS 4 4-) (Fig. (9)), which is a water soluble sensitizer used in photodynamic therapy [70]. Interestingly, the FA-DPPlsC/AlPcS 4 4-liposomes produced the broadest distribution pattern of intracellular AlPcS 4 4-, and they were significantly more phototoxic to KB cells (post irradiation) as compared to either free AlPcS 4 4-or its nontargeted liposome counterparts.…”

Section: Improving the Unloading Efficiency Of Fa-targeted Liposomesmentioning

confidence: 98%

Targeting Therapeutic and Imaging Agents to Folate Receptor Positive Tumors

Reddy

Allagadda²,

Leamon³

2005

CPB

110

View full text Add to dashboard Cite

The membrane-bound folate receptor (FR) is overexpressed on a wide range of human cancers, such as those originating in ovary, lung, breast, endometrium, kidney and brain. The vitamin folic acid is a high affinity ligand of the FR which retains its receptor binding properties when conjugated to other molecules. Consequently, "folate targeting" technology has successfully been applied for the delivery of protein toxins, chemotherapeutic agents, radio-imaging and therapeutic agents, MRI contrast agents, liposomes, gene transfer vectors, antisense oligonucleotides, ribozymes and immunotherapeutic agents to FR-positive cancers. These folate-bearing delivery systems have produced major enhancements in cancer cell specificity and selectivity over their non-targeted formulation counterparts. Hence, it is hopeful that this targeting strategy will lead to improvements in the safety and efficacy of clinically-relevant anti-cancer agents. Therefore, the focus of this review will be to highlight the current status of folate-targeted technology with particular emphasis on the recent advances in this field as well as possible directions for future development.

show abstract

Section: Improving the Unloading Efficiency Of Fa-targeted Liposomesmentioning

confidence: 98%

Targeting Therapeutic and Imaging Agents to Folate Receptor Positive Tumors

Reddy

Allagadda²,

Leamon³

2005

CPB

110

View full text Add to dashboard Cite

show abstract

“…DPPC is a neutral but nonfusogenic lipid of similar chemical structure with DOPE. 44 The hybrid nanoparticles with 60% DOTAP and 20% DPPC show similar diameter (68.9 ± 1.6 nm) and zeta potential (36.1 ± 1.2 mV), in comparison with nanoparticles containing 60% DOTAP and 20% DOPE (65.3 ± 4.3 nm in size and zeta potential of 37.9 ± 0.8 mV). To measure subcellular distribution of hybrid nanoparticles with 60% DOTAP and 20% DPPC, we coculture DiD-labeled nanoparticles with HUVEC cells for 24 h and observe the fluorescence with a confocal microscope.…”

Section: ■ Results and Discussionmentioning

confidence: 89%

Nonspecific Organelle-Targeting Strategy with Core–Shell Nanoparticles of Varied Lipid Components/Ratios

et al. 2016

View full text Add to dashboard Cite

ABSTRACT:We report a nonspecific organelle-targeting strategy through one-step microfluidic fabrication and screening of a library of surface charge-and lipid components/ratiosvaried lipid shell−polymer core nanoparticles. Different from the common strategy relying on the use of organelle-targeted moieties conjugated onto the surface of nanoparticles, here, we program the distribution of hybrid nanoparticles in lysosomes or mitochondria by tuning the lipid components/ratios in shell. Hybrid nanoparticles with 60% 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 20% 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) can intracellularly target mitochondria in both in vitro and in vivo models. While replacing DOPE with the same amount of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), the nanoparticles do not show mitochondrial targeting, indicating an incremental effect of cationic and fusogenic lipids on lysosomal escape which is further studied by molecular dynamics simulations. This work unveils the lipid-regulated subcellular distribution of hybrid nanoparticles in which target moieties and complex synthetic steps are avoided.

show abstract

“…A pH-sensitive and folic acid receptortargeted liposome designed to deliver water-soluble photosensitizer chloroaluminum phthalocyanine tetrasulfonate ([AlPcS (4) ] (4-) ) to tumor cells was prepared. 115 This dual-targeting formulation was significantly more phototoxic than free [AlPcS (4) ] (4-) and liposomal formulations that were either pHsensitive or folic acid receptor-targeted only. A novel approach to targeting folic acid receptors using LDL particles was recently reported.…”

Section: Folic Acid Receptormentioning

confidence: 92%

Enhancing Tumor Drug Delivery by Laser-Activated Vascular Barrier Disruption

Chen¹,

He²

2006

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. REPORT DATE PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERUniversity of the Sciences in Philadelphia Philadelphia, PA 19104 SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel CommandFort Detrick, Maryland 21702-5012 SPONSOR/MONITOR'S REPORT NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited SUPPLEMENTARY NOTESOriginal contains colored plates: ALL DTIC reproductions will be in black and white.14. ABSTRACT An obstacle for successful drug therapy for cancer is the existence of drug delivery barriers, which causes insufficient drug delivery to the tumor tissue. Because of inadequate drug delivery to the tumor tissue, the drug dose has to be increased, which leads to normal tissue toxicity. This delivery problem not only limits the clinical application of existing chemotherapeutics, but also decreases the effectiveness of many new drugs under development for prostate cancer. We found that vascular targeting photodynamic therapy (PDT), a modality involving the combination of a photosensitizer and laser light, is able to disrupt tumor vascular barrier, a significant hindrance to drug delivery. Therefore, tumor accumulation of circulating molecules is significantly enhanced, as demonstrated by intravital fluorescence microscopy and whole-body fluorescence imaging techniques. Immunofluorescence staining of endothelial cytoskeleton structure further indicates microtubule depolymerization, stress actin fiber formation and intercellular gap formation. Based on these results, we propose to use this laser-based therapy to enhance anticancer drug effectiveness. PDT is currently in worldwide multicenter clinical trials for the localized prostate cancer therapy. The available results indicate that PDT employing advanced laser fiber technology and sophisticated light dosimetry is able to treat localized prostate cancer in an effective and safe way. The combination of photosensitization with current chemotherapy or other new drug therapies will greatly improve clinical...

show abstract

Chloroaluminum phthalocyanine tetrasulfonate delivered via acid-labile diplasmenylcholine-folate liposomes: Intracellular localization and synergistic phototoxicity

Cited by 70 publications

References 59 publications

Targeting Therapeutic and Imaging Agents to Folate Receptor Positive Tumors

Targeting Therapeutic and Imaging Agents to Folate Receptor Positive Tumors

Nonspecific Organelle-Targeting Strategy with Core–Shell Nanoparticles of Varied Lipid Components/Ratios

Enhancing Tumor Drug Delivery by Laser-Activated Vascular Barrier Disruption

Contact Info

Product

Resources

About